Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.68 |
| ▸ | PGR | P06401 | 5/20 | 0.68 |
| ▸ | AR | P10275 | 4/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281837 | 1.00 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 | |
| SCHEMBL6408531 | 1.00 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 | |
| SCHEMBL4979442 | 1.00 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 | |
| SCHEMBL3275715 | 1.00 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 | |
| SCHEMBL3275721 | 1.00 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 | |
| SCHEMBL4982376 | 1.00 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 | |
| SCHEMBL6408534 | 1.00 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 | |
| SCHEMBL3281843 | 1.00 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 | |
| SCHEMBL4982380 | 1.00 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 | |
| SCHEMBL6406521 | 0.93 | NR3C1 (0.68) | NR3C1PGRARNR3C2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2005-09-29 | — | — | US | claimed |
| US-20040235809-A1 | Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2004-11-25 | — | — | US | claimed |
| US-20030220312-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | claimed |
| US-20020123485-A1 | Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2002-09-05 | — | — | US | claimed |
| EP-0831910-B1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | SEARLE & CO (US) | 2001-11-21 | — | — | EP | claimed |
| EP-0831910-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| US-20100204190-A1 | NEW COMBINATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-08-12 | — | — | US | disclosed |
| US-20090149431-A1 | Eplerenone Drug Substance Having High Phase Purity | BARTON KATHLEEN P | 2009-06-11 | — | — | US | disclosed |
| US-20070123498-A1 | Combination of organic compounds | SHETTY SURAJ S | 2007-05-31 | — | — | US | disclosed |
| US-20050267302-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | G.D. SEARLE & CO. (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050261261-A1 | Eplerenone drug substance having high phase purity | PHARMACIA CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| EP-1580193-A2 | Eplerenone crystalline form | Pharmacia Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050159594-A1 | Eplerenone crystal form exhibiting enhanced dissolution rate | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | disclosed |
| WO-2005039637-A2 | COMBINATIONS OF AN ALDOSTERONE RECEPTOR ANTAGONIST, A DIURETIC AND AN ANGIOTENSIN BLOCKER | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| EP-1505072-A2 | Eplerenone crystalline form exhiniting enhanced dissolution rate | Pharmacia Corporation (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20030083493-A1 | Eplerenone drug substance having high phase purity | BARTON KATHLEEN P (US) | 2003-05-01 | — | — | US | disclosed |
| US-20020045746-A1 | Eplerenone crystalline form | PHARMACIA CORPORATION | 2002-04-18 | — | — | US | disclosed |
| US-20020038021-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | PHARMACIA CORPORATION | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204190-A1 | NEW COMBINATIONS | OTC, CYP11B2, OAT | NR3C1 476/4885PGR 593/4885AR 1418/4885 |
| US-20020045746-A1 | Eplerenone crystalline form | NR3C2, MC2R, HSD11B2 | NR3C1 12/4885PGR 657/4885AR 28/4885 |
| US-20050159594-A1 | Eplerenone crystal form exhibiting enhanced dissolution rate | NR3C2, MC2R, HSD11B2 | NR3C1 19/4885PGR 197/4885AR 20/4885 |
| US-20050267302-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | NR3C2, MC2R, HSD11B2 | NR3C1 20/4885PGR 167/4885AR 23/4885 |
| US-20020038021-A1 | Eplerenone crystalline form exhibiting enhanced dissolution rate | NR3C2, MC2R, HSD11B2 | NR3C1 20/4885PGR 167/4885AR 23/4885 |
| US-20050261261-A1 | Eplerenone drug substance having high phase purity | NR3C2, MC2R, PTGER1 | NR3C1 8/4885PGR 261/4885AR 14/4885 |
| US-20030220312-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders | NR3C2, PTGER4, PTGER1 | NR3C1 76/4885PGR 646/4885AR 128/4885 |
| US-20040235809-A1 | Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure | ADRB1, ADRB2, NR3C2 | NR3C1 31/4885PGR 234/4885AR 112/4885 |
| US-20020123485-A1 | Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB2, ADRB1, NR3C2 | NR3C1 31/4885PGR 414/4885AR 120/4885 |
| US-20030083493-A1 | Eplerenone drug substance having high phase purity | NR3C2, MC2R, PTGER1 | NR3C1 8/4885PGR 261/4885AR 14/4885 |
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB1, ADRB2, ADRB3 | NR3C1 32/4885PGR 338/4885AR 76/4885 |
| US-20070123498-A1 | Combination of organic compounds | OTC, OAT, CYP11B2 | NR3C1 488/4885PGR 451/4885AR 936/4885 |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | PTGER1, KCNN4, HCN1 | NR3C1 68/4885PGR 981/4885AR 280/4885 |
| US-20090149431-A1 | Eplerenone Drug Substance Having High Phase Purity | NR3C2, MC2R, PTGER1 | NR3C1 8/4885PGR 261/4885AR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.